Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
Related Experiment Video
Updated: Oct 10, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Lin Tang1,2, Yicheng Feng1, Sai Gao1
1Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, China.
Abstract:
Glioblastoma (GBM) is the most common malignant primary brain tumor with a poor prognosis. The current standard treatment regimen represented by temozolomide/radiotherapy has an average survival time of 14.6 months, while the 5-year survival rate is still less than 5%. New therapeutics are still highly needed to improve the therapeutic outcome of GBM treatment. The blood-brain barrier (BBB) is the main barrier that prevents therapeutic drugs from reaching the brain. Nanotechnologies that enable drug delivery across the BBB hold great promise for the treatment of GBM. This review summarizes various drug delivery systems used to treat glioma and focuses on their approaches for overcoming the BBB to enhance the accumulation of small molecules, protein and gene drugs, etc. in the brain.
Insights
Glioblastoma (GBM) treatments face challenges due to the blood-brain barrier (BBB). Nanotechnology offers promising solutions for delivering therapeutics across the BBB to improve patient outcomes.
Area of Science:
- Neuro-oncology
- Nanomedicine
- Drug Delivery Systems
Background:
- Glioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis.
- Current treatments like temozolomide/radiotherapy offer limited survival benefits (14.6 months average, <5% 5-year survival).
- The blood-brain barrier (BBB) significantly impedes drug delivery to the brain, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review nanotechnological drug delivery systems for glioma treatment.
- To highlight strategies for overcoming the BBB to enhance therapeutic agent accumulation in the brain.
- To explore the potential of nanotechnology in improving GBM treatment outcomes.
Main Methods:
- Literature review of nanotechnologies for drug delivery across the BBB.
- Analysis of various drug delivery systems targeting glioma.
- Focus on methods to enhance brain drug penetration and accumulation.
Main Results:
- Nanotechnologies demonstrate potential for crossing the BBB.
- Various nanocarriers can deliver small molecules, proteins, and gene therapies to the brain.
- Enhanced drug accumulation in the brain is achievable through nanotechnology-based approaches.
Conclusions:
- Nanotechnology-based drug delivery systems are crucial for overcoming BBB limitations in GBM treatment.
- These systems hold promise for improving the efficacy of therapeutics for malignant brain tumors.
- Further research into nanomedicine is essential for advancing GBM therapy.
